Yufei Xia

This paper introduces an adjuvant (iCTA) that enhances in vivo CAR-T therapy against solid tumors by improving T-cell recruitment, antigen presentation, and tumor microenvironment.

This paper develops a structure-guided RSV vaccine platform with stabilized prefusion F immunogens and mucosal delivery, showing protection in animal models and advancing to clinical trials.

This paper develops a lipid nanoparticle strategy to enhance CAR-T cell persistence and antitumour efficacy in solid tumours by targeting primary lymphoid tissues.

This study investigates FUS-ERG fusion oncoprotein-DNA co-condensates, revealing nested asymmetric phase separation and their potential for DNA-based information manipulation.